As a nation where 90% of all people living with HIV know their diagnosis and are being treated, Germany has made great strides to advance its HIV care goals.
Gilead partners with various organizations that support people living with breast cancer. One such organization, the Young Survival Coalition (YSC), recognizes the unique needs of people of childbearing age and works with patients under 40.
Gilead Sciences, Inc. (Nasdaq: GILD) announced it is providing a total of $12.6 million in grant funding to 19 organizations working to improve the HIV landscape for Black women and girls in the United States.
At Gilead, we’re focused on fighting devastating diseases and delivering innovative medicines that offer new hope for patients. Also important, though, is our work to make sure that we remove barriers to care and reach the people that need our therapies.
Long-time liver specialist Carrie Frenette says she won’t ever forget the people she treated for hepatitis C (HCV) before 2013 – the year that the Food and Drug Administration (FDA) approved a Gilead medicine. The medicine was the first curative therapy for HCV.
We’re proud to offer an inclusive culture that enables all people to do their best work, and we’re happy to be named one of Newsweek America’s Greatest Workplaces for Diversity for our efforts.
The personal journeys of six people in the United Kingdom living with HIV, hepatitis C and cancer – and the challenges they face due to stigma and health inequities – come together in the form of a new, intentionally difficult-to-read book from Gilead.
Gilead’s Corporate Social Responsibility (CSR) Report provides an overview of the work the company is doing around the world to improve the lives of...